#USA #Singapore #Emerald Clinical Trials #Glenn Kerkhof #Mary Gunn

Emerald Clinical Trials Announces Leadership Change

Emerald Clinical Trials, a prominent player in the global clinical research sector, has officially announced a significant leadership transition. On July 30, 2025, the organization revealed that Mary Gunn has stepped down as CEO, effective immediately. This pivotal change comes as the company seeks to maintain stability and forward momentum in its operations.

In light of Gunn's departure, the Board of Directors has appointed Glenn Kerkhof, a seasoned executive within the clinical research organization (CRO) field and a long-standing board member, as Interim CEO. The choice of Kerkhof reflects the company's commitment to ensuring a seamless transition as it embarks on a search for a permanent CEO.

Sean Carney, Chair of the Board, expressed gratitude for Gunn's contributions to Emerald, highlighting the organization’s status as a leading CRO with extensive global capabilities: "We thank Mary for her contributions. With Glenn stepping in as Interim CEO, we are confident in our ability to maintain momentum and deliver for our clients."

Glenn Kerkhof brings an impressive 30 years of experience in clinical research and pharmaceutical services to the role. His previous leadership as CEO of Chiltern saw the company undergo significant international expansion, and he also served as Executive Chairman of George Clinical, which is now known as Emerald Clinical Trials. This unique blend of experience positions him well to navigate the organization through this transitionary phase.

As Interim CEO, Kerkhof intends to focus on a smooth transition and robust delivery for clients while supporting the team’s global efforts. "Emerald Clinical's strengths lie in our therapeutic focus, scientific depth, and close client partnerships," Kerkhof stated. "I am committed to building on our momentum and leading with clarity and purpose." His vision aims to foster confidence among clients and stakeholders that Emerald will continue to provide exceptional service and meet the demands of the clinical research landscape.

Founded with the mission of delivering operational excellence and scientific innovation, Emerald Clinical Trials operates on a global scale, currently serving over 100 biotechnology firms and six of the top ten pharmaceutical companies. The organization is headquartered in Singapore, where it capitalizes on its operational expertise to provide comprehensive clinical trial services across various trial phases.

As the search for a permanent CEO begins, this transition represents a crucial period for Emerald Clinical Trials, which stands poised to retain its leadership status in the industry under Kerkhof's stewardship. Stakeholders are encouraged to stay updated on the developments and any forthcoming announcements.

For further information on Emerald Clinical Trials and its fully integrated clinical solutions, visit www.emeraldclinical.com.

Emerald Clinical Trials is committed to resilience and innovation as it shapes the future of clinical research globally.